Efficient Delivery Solutions from Creative Biolabs
SHIRLEY, NY, UNITED STATES, February 25, 2025 / EINPresswire.com / -- Gene therapy has tremendous promise in curing diseases that have been declared untreatable, but the delivery systems must be effective and precise for success. Creative Biolabs is proud to announce that, being a global biotechnology and life sciences leader, it has developed state-of-the-art gene therapy solutions to fast-track the development of next-generation therapeutics. This technology empower scientists and pharmaceutical companies with powerful tools to enhance research efficacy and reduce off-target effects.
Creative Biolabs' lipid nanoparticle platform is designed to encapsulate and deliver nucleic acids (such as siRNA, mRNA, or DNA) with high efficiency. The LNP can be optimized for maximum stability, biocompatibility, and tissue-specific targeting and are amenable to a wide range of gene therapy development research.
Synthesis Service of ARCs and AOCs
Creative Biolabs is also expanding its service portfolio to include antibody-siRNA conjugates (ARCs) and antibody-oligonucleotide conjugates (AOCs), two powerful approaches combining the targeting specificity of antibodies with the silencing capabilities of RNA molecules.
'We have devised several ways to synthesize ARCs and AOCs. For instance, we can conjugate siRNA onto antibodies using non-covalent interactions or covalent binding to lysine or cysteine residues that are positioned within the antibody structure. This possible methodology has the power to treat multiple ailments by utilizing both the antibodies' specific identification and the gene-silencing abilities of siRNA,' one scientist explained.
GalNAc-siRNA Therapeutics Development
To further enable the growing demand for RNA-based therapies, Creative Biolabs is also offering custom GalNAc (N-acetylgalactosamine) conjugation services to enhance the tissue-specific delivery of RNAi therapeutics.
Scientists at this firm have great experience in this area, having the capacity to introduce chemical modifications that would boost the stabilization and activities of these GalNAc-siRNA conjugates.
'We are excited to introduce these cutting-edge solutions, which represent a significant advancement in RNA delivery and targeting technology,' said the manager of Creative Biolabs. 'Working with us, researchers can obtain breakthroughs faster and overcome delivery challenges.'
As a leading provider in the biotechnology field, Creative Biolabs is repeatedly pushing the transition of gene therapy and RNA-based technology. The newly launched services further show their determination to serve their clients in the latest development of gene therapy.
To learn more, please go to https://www.creative-biolabs.com/gene-therapy/.
About Creative Biolabs
Creative Biolabs is a trusted partner in the biotechnology and life sciences industry, offering one-stop solutions and services to support the discovery and development of new gene therapies and RNA-based therapies. Dedicated to quality and innovation, the company serves customers around the world in their pursuit of groundbreaking discoveries.
Candy Swift
Creative Biolabs
+1 631-830-6441
Legal Disclaimer:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds
King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 928,596 shares of common stock of the Company originally issued in December 2024 and January 2025, having exercise prices between $2.00 and $3.00 per share. Warrants to purchase 100,000 shares of common stock at the existing exercise price of $2.00 per share will be exercised at their existing exercise price of $2.00 per share and warrants to purchase 828,596 shares of common stock will be exercised at a reduced exercise price of $2.485 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statement on Form S-1 (No. 333-284381). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $2.5 million, prior to deducting placement agent fees and offering expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash and the payment of additional $0.125 per new unregistered warrant (additional $232,149 in the aggregate, which are included in the gross proceeds to the Company), the exercising holders will receive new unregistered warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "1933 Act"). The new warrants will be exercisable for an aggregate of up to 1,857,192 shares of common stock, at an exercise price of $2.485 per share and will be immediately exercisable upon issuance and (i) will have a term of twenty-four months with respect to new warrants to purchase up to 1,538,596 shares of common stock and (ii) will have a term of five years with respect to new warrants to purchase up to 318,596 shares of common stock, in each case, following the effective date of the resale registration statement registering the shares of common stock issuable upon exercise of the new warrants. The offering is expected to close on or about July 28, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes. The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the 1933 Act and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The on-going Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers. For additional information, visit the Company's website, Forward-Looking Statements completion of the offering, the satisfaction of customary closing conditions related to the offering and the anticipated use of proceeds therefrom. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the completion of the offering, the satisfaction of customary closing conditions related to the offering and the anticipated use of proceeds therefrom. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law. Contact:Phio Pharmaceuticals Phillips: jphillips@ Affairs To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
6 days ago
- Associated Press
Creative Biolabs Debuts Platforms for Smarter T Cell Stimulation
Creative Biolabs delivers tailored T cell activation solutions using hydrogel matrices, DNA scaffolds, and synthetic systems for precise and efficient immune modulation. Creative Biolabs, the global pioneer in immunotherapy, has developed novel artificial T cell-stimulating platforms —like hydrogel matrices, DNA scaffolds, and synthetic systems—to enhance CAR-T, TCR-T, and adoptive cell therapy research in oncology and immunology. Activation of T cells is also a key issue in cancer immunotherapy, especially as researchers seek more physiologically relevant conditions in which to optimize cell growth, survival, and activity. Creative Biolabs' artificial platforms replicate the most critical aspects of the original lymphoid microenvironment—enabling antigen-specific stimulation and controlled co-signal presentation that reduce activation-induced death and provide for long-lasting immunity. One of the newly announced technologies is a hydrogel-based artificial T cell-stimulating platform, which includes tunable formats such as artificial T cell-stimulating matrices (aTM), artificial lymph node scaffolds (aLN), and immunomodulatory macroporous hydrogels. The platforms enable the possibility of accurately modulating the stiffness of the matrix and biochemical ligand density, triggering localized immune activation with a low off-target effect. Complementing these is the DNA-based platform, which uses self-assembled DNA scaffolds to mimic dendritic cell architectures. With tunable conjugation protein ratios and high surface-to-volume efficiency, researchers can modulate multi-signal stimulation profiles to fit therapeutic design parameters. The platform further improves functional antibody display and allows for scalable stimulation approaches. 'Our tools bridge the gap between engineering precision and biological complexity,' said a Creative Biolabs senior R&D director. 'By simulating the critical immunological signals with synthetic and bioinspired materials, we're empowering scientists to accelerate discovery and improve cell product quality.' In addition to proprietary technology, Creative Biolabs offers end-to-end service customization in processes like DNA scaffold design, molecular engineering, protein functionalization, and in vitro / in vivo testing. Each workflow is supported by GLP-grade quality systems and high-throughput facilities to offer reproducibility and data integrity during the experimental stages. Customers are not only offered cutting-edge platforms but also professional advice and flexible project delivery. Creative Biolabs' team of specialists ranges from immunology, synthetic biology, and materials science to offer cross-functional support that is tailored to achieve every research goal. With applications from antigen-specific T cell screening to potency optimization and the development of novel therapeutics, artificial stimulation platforms hold the promise of transforming the evaluation and scaling of cell therapies. Creative Biolabs is leading innovation in this space, committed to enabling global partners to unlock the full potential of immune-based therapeutics. For additional information or to obtain a custom quote, visit About Creative Biolabs Creative Biolabs is a leader in immunotherapy, delivering customized artificial T cell-activating platforms for CAR-T and TCR-T studies. Their hydrogel, DNA, and synthetic platforms replicate critical immune signals, optimize activation efficiency, and facilitate scalable therapies—uniting engineering accuracy and biological sophistication to propel global cell therapy innovation. Media Contact Company Name: Creative Biolabs Contact Person: Candy Swift Email: Send Email City: Shirley State: New York 11967 Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Creative Biolabs Debuts Platforms for Smarter T Cell Stimulation
Yahoo
15-07-2025
- Yahoo
Wave Life Sciences Unveils Promising Preclinical Data for Obesity Treatment WVE-007 at ADA Scientific Sessions
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the best low priced pharma stocks to buy now. From June 20 to 23, Wave Life Sciences presented preclinical data for WVE-007, which is its investigational GalNAc-siRNA targeting INHBE mRNA, at the American Diabetes Association's 85th Annual Scientific Sessions in Chicago. The oral presentation was delivered on June 21 and highlighted WVE-007 as a potential novel and distinct obesity treatment designed to induce healthy weight loss by reducing fat while preserving muscle mass. WVE-007 functions by silencing INHBE mRNA, which in turn reduces the production of Activin E protein. Activin E is a lipolysis suppressor that is upregulated in obesity. By inhibiting Activin E, WVE-007 promotes lipolysis, or fat breakdown. A biotechnology laboratory filled with computers and equipment to support research. Human genetics provides strong support for INHBE as a therapeutic target. Individuals with a protective loss-of-function variant in one copy of the INHBE gene exhibit a healthier cardiometabolic profile, which includes less abdominal fat, lower triglycerides, and reduced risk of type 2 diabetes/T2D and cardiovascular disease/CAD. These individuals also show favorable associations with liver traits, such as reductions in cT1 (reflecting liver inflammation and fibrosis) and ALT (reflecting liver damage), without impacting liver fat. Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology company that designs, develops, and commercializes ribonucleic acid/RNA medicines through PRISM, which is a discovery and drug development platform. While we acknowledge the potential of WVE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
